Bone marrow transplant much safer, easier to find donor match now
What are the latest advances in bone marrow transplant (BMT)?
Earlier, patients had to wait for a perfectly matched donor, like finding a key that fits a lock exactly. Now, with haploidentical transplants (half-matched donors), a parent, child or sibling can be the donor. This has been a game-changer in India, where full matches are rare. We also have more precise HLA typing (compatibility testing) to reduce rejection risk, and gentler conditioning treatments to prepare the body, especially helpful for children and older patients. A major advance is preventing graft-versus-host disease (GVHD), where the new donor cells see your body as 'foreign' and attack it. Today, special medicines can 'teach' these cells to live in harmony with one's body.
What is the current research direction in BMT?
Research is moving towards making BMT safer, faster, and more widely available. One breakthrough is gene therapy, instead of replacing bone marrow, we can correct faulty genes in the patient's own stem cells. This is showing promise in thalassemia and sickle cell disease. In cancer care, CAR-T cell therapy is making headlines. Sometimes this is used alongside BMT for better results. Reduced-intensity conditioning is another innovation, allowing older or medically fragile patients to have BMT with fewer side effects.
Has any progress been made in India towards research in BMT?
India has made remarkable progress in BMT over the last decade. One of our biggest achievements is mastering haploidentical transplants at much lower cost compared to Western countries, but with similar success rates. Given that only 25–30% of Indian patients find a fully matched sibling donor, this has been life-changing. Indian research also focuses on faster, cost-effective infection detection, because early treatment in the first few weeks post-transplant can save lives. Nutrition is another area where we have developed tailored diet plans to improve immunity in patients who may be malnourished before transplant. We're building large donor registries and spreading awareness about stem cell donation to expand our options for patients.
Who is eligible for BMT and when is it required?
BMT is used when the bone marrow is producing harmful cells or has stopped working. This includes blood cancers, aplastic anaemia, and genetic disorders.
There are two types of transplants: autologous and allogeneic. In autologous, the patient's own healthy stem cells are collected, stored, and given back after treatment. In allogeneic, stem cells are taken from a donor, either a full match or a half match.
Timing is key. In some cancers, early BMT offers the best cure rates; in others, we wait until other treatments have failed.
What are the precautions needed to be taken after a bone marrow transplant?
The first year after BMT is like caring for a newborn, the immune system is brand new and needs protection. In hospitals, patients stay 3–6 weeks in a protective room until the new marrow starts producing healthy blood cells, called engraftment. At home, hygiene is crucial: boiled or filtered water, freshly cooked food, avoiding crowds, and regular handwashing. Medicines to prevent rejection and infections must be taken exactly as prescribed. Follow-up visits are essential. Physical strength returns slowly, and most patients can resume work, school, or normal activities in 6–12 months. Emotional recovery is equally important, and counselling helps.
What should patients or parents know before going for BMT?
BMT is a life-saving treatment, but it requires preparation. One needs to understand the steps: finding a donor, pre-transplant treatment to prepare the body, infusing healthy stem cells, and recovery. Financial planning is important as costs include treatment, medicines, and follow-up. Most importantly, choose a hospital with an experienced team and strong infection control.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
26 minutes ago
- Hans India
IIT Delhi's new method to cut textile waste, recycle discarded denims to good quality garments
New Delhi: A team of researchers from IIT Delhi has developed a new method to recycle denim waste to knitted garments without compromising quality. The findings will also help reduce textile waste -- the discarded textiles and clothing after their use -- which end up in landfills. India accumulates around 3.9 million tonnes of domestic post-consumer textile waste annually, of which only 4 per cent is recycled. Those recycled lose fibre strength and face variability in colour and quality. However, with the novel method, the IIT researchers found that up to 50 per cent of recycled yarns can be used in knitted clothing without deteriorating the feel of the product. 'To reduce the roughness of recycled yarns, a softening treatment was applied to the fabric, which ensured that the tactile feel of the final product is the same as that of virgin products, said Prof Abhijit Majumdar, Dept. of Textiles and Fibre Engineering, IIT Delhi. 'We have demonstrated our work with denim waste, and it can be extended with any other textile waste,' he added. In the study, detailed in the Journal of Cleaner Production, the team recycled waste denim into yarns, ensuring minimum damage to the fibre properties by optimising the process conditions. Recycled yarns were then blended into knitted fabric using the seamless whole garment technology. Knitted garments were produced, varying the recycled yarn content from 25 per cent to 75 per cent. Another key aspect of this research was to quantify the environmental benefits through life cycle assessment (LCA) in the Indian context. Analysis by the IIT Delhi team showed that around 30-40 per cent of environmental impacts can be mitigated in terms of greenhouse gas emission, acid rain, and fossil fuel depletion, whereas for ozone layer depletion, it is around 60 per cent. As the use of recycled fibres could reduce the use of virgin cotton, the pesticides, fertilisers and water used for cultivation can also be saved. Among the processes involved, the cotton cultivation stage itself contributes 24 per cent to global warming, making the virgin yarns less environment-friendly. 'The research team is now exploring the possibility of recycling textile waste materials multiple times,' added Prof B.S. Butola, Dept. of Textile and Fibre Engineering, IIT Delhi.
News18
an hour ago
- News18
Hyderabad Pharma Firm To Make Drug For Hard-To-Treat Bladder Cancer After Local Trials Waiver
For Indian patients battling aggressive bladder cancer driven by specific gene changes, a vital treatment may soon be available. Citing an 'unmet medical need" India's top drug advisory panel has approved a pharmaceutical firm's request to make and sell erdafitinib tablets in India by skipping a local third-phase trial but needing a post-launch fourth phase study. Hyderabad-based Natco Pharma has presented the proposal for the grant of permission to manufacture and market erdafitinib in three different strengths along with the 'justification" for a waiver on local third-phase clinical trials, as per the minutes of the meeting of the technical committee dated July 17. 'After detailed deliberation, the committee opined that there is an unmet medical need for the proposed indication in the country," said the minutes, which were accessed by News18. 'The committee recommended for the grant of permission to manufacture and market the drug Erdafitinib Tablet 3 mg, 4 mg and 5 mg with local Phase III clinical trial waiver." This marks a significant shift from the 2023 stance, when the subject expert committee (SEC), functioning under Central Drugs Standard Control Organisation (CDSCO), had rejected Natco's request for a Phase-III waiver. After reviewing the bioequivalence data, the SEC asked the company to 'submit the Phase-III clinical trial protocol before the committee for further consideration". That earlier decision underscored the caution about approving cancer treatments without robust local safety and efficacy data. According to the GLOBOCAN 2020 database, bladder cancer is the 17th most common malignancy in India. The five-year prevalence appears to be 3.57 per 1,00,000 population, leading to about 11,000 deaths each year. The incidence of bladder cancer is higher in males as compared to females. Data shows that bladder cancer incidence does vary across India. Among males, Delhi had the highest incidence rates followed by Thiruvananthapuram and Kolkata, and the lowest rate was in Dibrugarh. When it comes to females, the rate is highest in Delhi followed by Mumbai and Mizoram, respectively, and lowest in Barshi. Over time, bladder cancer incidence has increased in Delhi, Bengaluru and Mumbai, while it has decreased in Chennai. WHAT MAKES ERDAFITINIB IMPORTANT? Erdafitinib is a targeted therapy that inhibits the fibroblast growth factor receptor (FGFR) – a key driver of rapid tumour growth in certain bladder cancers. The FGFR gene gives the body instructions to make FGFR proteins, which sit on the surface of cells. These proteins receive growth signals (called fibroblast growth factors) and tell the cell when to grow, divide, or repair itself. On January 19, 2024, the US FDA approved erdafitinib, sold under the brand name Balversa, developed by Janssen Biotech, a Johnson & Johnson company. The drug has been approved for adults with advanced or metastatic bladder cancer that has certain FGFR3 gene changes, confirmed by an approved test. It can be used if the cancer has worsened after at least one previous systemic treatment. It is not meant for patients who could still benefit from PD-1 or PD-L1 immunotherapy and have not yet tried it. ONCOLOGISTS WELCOME THE MOVE According to the sellers on the online platform Indiamart, the bottle containing 56 tablets of 4mg Erdafitinib is sold at Rs 7,000, which is Rs 125 per tablet. With local manufacturing, however, the cost is expected to drop by more than 50 per cent. 'It's a good drug for bladder cancer patients with locally advanced disease not responding to chemotherapy. This is targeted therapy that blocks fibroblast growth factor receptor (FGFR). This fibroblast growth factor helps cancer grow fast. This medicine blocks this growth and helps control cancer," said Dr Satya Prakash Yadav, director of paediatric haematology-oncology and bone marrow transplant at Medanta Hospital. Similarly, Dr Pragya Shukla, who leads the clinical oncology department at Delhi State Cancer Institute, said the drug is for FGFR-altered metastatic urothelium, which has failed on multiple lines of chemotherapy and has shown benefits in overall survival in this particular group of patients. As the panel cited 'unmet demand", Dr Shukla said: 'The drug should definitely benefit a particular group of patients waiting for a targeted therapy." WHAT COMES NEXT? If the technical committee's recommendation is adopted into a final CDSCO order, Natco Pharma may roll out erdafitinib across India – provided it submits a robust Phase-IV study protocol within three months of approval. A fourth phase trial is the stage of research that happens after a drug has been approved by regulators and is already being sold in the market. It is also called post-marketing surveillance or post-approval study. It can reveal safety issues, interactions, or benefits that did not appear in smaller or shorter trials before, and at times lead to changes in how the drug is prescribed – or even withdrawal if serious risks are found.
Hindustan Times
2 hours ago
- Hindustan Times
Govt issues note on birth, death registration
Dr Babita Kamlapurkar, deputy director, health services issued a note on Monday on mandatory registration of births and deaths. For births or deaths at home, the head of the family is responsible for reporting them, officials said, adding that birth registration can be done without a name, which can be added later. (REPRESENTATIVE PHOTO) 'The first copy of a birth or death certificate is issued free of cost and additional copies can be obtained on payment. Corrections are allowed under certain conditions, and foreign births can be registered at Indian embassies abroad and later in India, though foreign deaths cannot be registered here,' she said. The Registration of Births and Deaths Act, 1969, implemented by the central government, governs the registration process. For births or deaths at home, the head of the family is responsible for reporting them, officials said, adding that birth registration can be done without a name, which can be added later. Delay in registration of birth and death by one year needs a magistrate's order and requisite fee.
